Credit By: Khaleej Times
The first phase of the Longevity 1.0 trials conducted by the healthcare group PureHealth in the UAE has shown promising results. Over 100 participants experienced an average increase in life expectancy by 2.2 years after engaging in the 90-day trials.
Key findings from Longevity 1.0 include:
- Improved Biomarkers: Under clinical supervision, participants achieved improved biomarkers through exercise and a healthier diet.
- Diabetes Risk Reduction: At the trial’s start, 9 participants were at risk of diabetes. After 90 days, only 3 participants were classified as at risk.
- Increased Physical Activity: The level of physical activity among participants increased by 25%, with the most active group losing an average of 3.5kg.
PureHealth launched the Longevity 1.0 trials to add up to 25 additional years to the average life expectancy of residents over the next 50 years. The campaign aims to extend life while prioritizing health spans, making people healthier for longer.
Dr. Asma Al Mannai, Executive Director of the Research and Innovation Centre at the Department of Health in Abu Dhabi, emphasized the significance of such initiatives in positioning Abu Dhabi as a global healthcare innovation hub.
The next phase, Longevity 2.0, seeks to combat common age-related diseases and extend the life spent in good health. With over 3,000 participants, the campaign focuses on improving biomarkers through healthier lifestyle choices such as diet, exercise, and avoiding smoking.
The ultimate goal is to increase the UAE’s life expectancy from the current 76 years to 101 years, addressing aging as a critical factor in health outcomes. The success of these trials reflects a concerted effort to transform Abu Dhabi into a blue zone city, where residents live longer and healthier lives compared to the global average.
Follow ARP Media for more informative blogs.